Indaptus Therapeutics is trading 13.5% down at $1.57 as investors engage in profit-taking and short-term selling following a sharp multi-day rally.
- The stock recently experienced a 5% gain on July 29 and a 6.6% jump in pre-market action before today’s reversal.
- No new company-specific news or fundamental catalysts have been reported, suggesting the decline is a technical reaction to recent price strength rather than fresh developments.